Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
37.3000
6.7000
No
99.0000
No
No
No
No
No
No
γ-Linolenic acid (γ GLA) is a polyunsaturated fatty acid with significant biological activity, belonging to the ω-6 fatty acid family, with the molecular formula C18H30O2 and CAS number 506-26-3. As a naturally occurring fatty acid, GLA is produced in the human body through the metabolic transformation of linoleic acid and is widely found in various vegetable oils. In recent years, with deeper research into the mechanisms of fatty acids in physiological and pathological processes, GLA has gradually become a research hotspot in the field of natural product pharmacology due to its unique anti-inflammatory, antioxidant, anti-tumor, and neuroprotective multiple pharmacological activities. By regulating multiple cellular signaling pathways, especially key molecules such as NF-κB and MAPK (including ERK1/2 and JNK), it exerts a wide range of biological effects and demonstrates potential application value in the treatment of inflammatory diseases, neurodegenerative diseases, and tumors.
This paper aims to systematically review the chemical structure and physicochemical properties, plant origins, and extraction methods of γ-linolenic acid, delve into its pharmacological activity and mechanism of action, analyze its pharmacokinetic characteristics combined with druggability parameters, and finally look ahead to its clinical application prospects, providing theoretical support and reference for subsequent basic and clinical research.
γ-linolenic acid (GLA) is a long-chain fatty acid composed of 18 carbon atoms, containing three cis double bonds located at positions 6, 9, and 12, making it a typical polyunsaturated fatty acid. Its molecular weight is 278.43, and its molecular formula is C18H30O2. The structural formula of GLA can be briefly described as 18:3 (ω-6), meaning that starting from the terminal of the fatty acid methyl group, the first double bond is located at the sixth carbon atom.
In terms of physicochemical properties, GLA is a colorless to pale yellow oily liquid with high hydrophobicity, a LogP value of about 6.7, indicating strong lipophilic properties. The polar surface area (TPSA) is 37.3 Ų, and the number of hydrogen bond acceptors is 2, indicating low molecular polarity. GLA is difficult to cross the blood-brain barrier (BBB), suggesting that its direct role in the central nervous system may be limited. Its LD50 value is about 2000 mg/kg, indicating low acute toxicity. In vitro toxicology assessment showed that GLA showed no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and Ames-induced mutagenic tests were also negative, indicating good safety and suitability for further drug development.
GLA is widely found in various vegetable oils, with Borage oil (Borago officinalis), evening primrose oil (Oenothera biennis), blackcurrant seed oil (Ribes nigrum), and borage seed oil being the main sources. The GLA content in these plant seed oils can reach as high as 15%-25%, making them the main raw material for industrial GLA extraction.
The extraction methods mainly include solvent extraction techniques, cold pressing, and supercritical CO2 extraction. Traditional solvent extraction usually uses organic solvents such as hexane and ethanol, combined with refining processes such as degumming, decolorization, and deodorization to obtain high-purity GLA oils and fats. Cold pressing is gaining popularity because it avoids high-temperature destruction of unsaturated fatty acid structures, but its extraction efficiency is relatively low. Supercritical CO2 extraction technology, known for its environmental friendliness, residue-free nature, and excellent selectivity, has become a research hotspot in recent years. It can effectively protect the active components of GLA and improve extraction purity and yield.
Moreover, with the development of biotechnology, research on genetically engineered microbial fermentation for GLA production is gradually underway, providing new approaches for large-scale, controllable production.
The anti-inflammatory effect of GLA is one of the most extensively studied pharmacological effects. GLA and its metabolites (such as eicosatrienoic acid, DGLA) can regulate the synthesis of inflammatory mediators and inhibit the expression of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. Mechanistically, GLA inhibits activation of the nuclear factor κB (NF-κB) signaling pathway, reduces transcription of inflammatory genes, and lowers the amplification of cascading inflammatory responses. Additionally, GLA can inhibit phosphorylation of ERK1/2 and JNK, members of the mitogen-activated protein kinase (MAPK) family, further suppressing inflammatory signaling.
Multiple studies in vivo and in vivo have confirmed that GLA has a good alleviating effect on chronic inflammatory diseases such as rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease. Its safety and oral activity make it an ideal candidate for natural anti-inflammatory agents.
The mechanism of GLA in tumor cells mainly involves inducing apoptosis and inhibiting tumor cell proliferation. Research has found that GLA can activate mitochondrial pathways by regulating intracellular redox states, promoting cytochrome C release, activating the caspase family, and ultimately inducing cancer cell apoptosis. Additionally, GLA reduces anti-apoptotic protein expression by inhibiting the NF-κB signaling pathway, thereby enhancing tumor cells' sensitivity to chemotherapy drugs.
Among various cancer models, GLA has demonstrated the potential to inhibit the growth of breast, colon, and prostate cancers, with significantly reduced side effects compared to traditional chemotherapy drugs, indicating promising prospects for adjuvant therapy.
GLA has significant antioxidant activity, scavenging free radicals, reducing lipid peroxidation, and protecting the integrity of cell membrane structures. Its antioxidant effects are mainly achieved by regulating the activities of intracellular antioxidant enzymes such as glutathione peroxidase (GPx) and superoxide dismutase (SOD). This action is of great significance for preventing oxidative stress-related diseases such as atherosclerosis, diabetes, and neurodegenerative diseases.
Although GLA does not easily cross the blood-brain barrier, its metabolites and indirect regulatory effects have attracted significant attention for its use in neurological diseases. GLA can regulate neuroinflammatory responses, reduce nerve cell damage, and promote nerve regeneration. Animal experiments have shown that GLA supplementation can improve cognitive function and enhance learning and memory abilities, suggesting its potential as an adjunct treatment for Alzheimer's disease and other neurodegenerative disorders.
The biological effects of GLA are mainly realized through multiple signaling pathways:
NF-κB signaling pathway
NF-κB is a core transcription factor regulating inflammation and immune responses. GLA inhibits IκB kinase (IKK) activity, prevents IκB degradation, suppresses NF-κB nuclear translocation, reduces pro-inflammatory gene expression, and exerts anti-inflammatory effects.
MAPK signaling pathway (ERK1/2 and JNK)
MAPK family members ERK1/2 and JNK participate in cell proliferation, differentiation, and stress responses. GLA inhibits its phosphorylation, blocks downstream signaling, and suppresses inflammatory responses and tumor cell proliferation.
Mitochondrial apoptosis pathway
GLA induces loss of mitochondrial membrane potential in cancer cells, promotes the release of cytochrome C, activates caspase-9 and -3, and initiates apoptosis.
Regulation of antioxidant enzymes
GLA regulates the Nrf2-ARE signaling pathway, promotes antioxidant enzyme expression, enhances cellular antioxidant capacity, and reduces oxidative stress damage.
Additionally, GLA metabolites such as DGLA can be converted into anti-inflammatory prostaglandins (PGE1), further enhancing their anti-inflammatory and immunomodulatory effects.
The druggability parameters of GLA indicate good safety and drug compatibility. Its higher LogP value indicates that GLA has good lipid solubility, which facilitates cell membrane penetration, but may also limit its water solubility and bioavailability. GLA has a relatively low polar surface area and a limited number of hydrogen bond acceptors, which matches the characteristics of lipid-soluble molecules.
Toxicological evaluation showed that GLA showed no significant hepatotoxicity, cardiotoxicity, or mutagenicity, and a high LD50 value suggests low acute toxicity, making it suitable for long-term oral use. GLA does not inhibit hERG ion channels, reducing the risk of arrhythmias.
Pharmacokinetics, GLA is mainly absorbed in the intestines after oral administration, metabolized by the liver into DGLA and other metabolites, and subsequently distributed in plasma and tissues. It is difficult to cross the blood-brain barrier, limiting its direct effect in the central nervous system. GLA has a moderate half-life, making it suitable for daily supplementation and therapeutic use.
To improve the bioavailability and targeting of GLA, research is underway on novel delivery systems such as nanocarriers, liposomes, and eutectic formulations.
Due to its multiple pharmacological activities and excellent safety profile, GLA has shown broad application prospects in clinical research for various diseases.
Inflammatory diseases
Including rheumatoid arthritis, atopic dermatitis, asthma, and inflammatory bowel disease, GLA improves quality of life by regulating inflammatory mediators, alleviating symptoms, and improving quality of life. Some clinical trials have confirmed that GLA supplements have positive effects in relieving joint pain and skin inflammation.
Oncology adjuvant therapy
As a natural anticancer agent, GLA can enhance the efficacy of chemotherapy drugs, reduce side effects, and improve patient outcomes. More randomized controlled trials are needed in the future to verify its safety and efficacy.
Neurological diseases
Although GLA does not easily cross the blood-brain barrier, its anti-inflammatory and antioxidant effects hold promise as an adjunct therapy for neurodegenerative diseases. Combination strategies with other neuroprotective agents are worth in-depth study.
Metabolic diseases
GLA regulates inflammation and oxidative stress in diabetes and cardiovascular diseases, and may become part of comprehensive treatment plans in the future.
Looking ahead, with advances in molecular biology and drug delivery technologies, targeted therapy and personalized medication for GLA will become research priorities. GLA-based derivative designs and their synergistic studies with other drugs will also drive their clinical translational progress.
γ-linolenic acid, as an important natural polyunsaturated fatty acid, shows broad application prospects in anti-inflammation, anti-cancer, antioxidant, and neuroprotective fields due to its unique chemical structure and diverse biological activities. Its mechanism of action involves regulation of multiple signaling pathways, and it has good safety and druggability. In the future, by integrating modern drug development technologies, in-depth exploration of GLA's pharmacokinetic characteristics and clinical efficacy will provide a solid foundation for its application in inflammation, oncology, and neurological diseases, promoting it as an important drug candidate in natural product pharmacology.
